CTOs on the Move

RiboCor

www.ribocor.com

 
RiboCor is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.ribocor.com
  • 7077 Northland Cir N Ste 100
    Minneapolis, MN USA 55428
  • Phone: 763.746.3910

Executives

Name Title Contact Details

Similar Companies

Karius

Karius is a life sciences company focused on generating genomic insights for infectious diseases with a non-invasive blood test that helps clinicians make rapid treatment decisions. By mapping each patient`s microbial landscape from a single blood draw, Karius moves closer to a vision of a world where infectious disease is no longer a major threat to human health.

Eurofins

Eurofins is a Des Moines, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

GenapSys

GenapSys is a company focused on the advancement of universal access to genomic information by delivering an affordable, scalable, and accurate genomic sequencing ecosystem that empowers both academic and clinical research applications. Its system leverages a proprietary electrical microfluidic sequencing chip with a scalable number of detectors, allowing for a wide range of applications. GenapSys is headquartered in Redwood City, CA. GenapSys products are provided for Research Use Only. Not for use in diagnostic procedures.

CureVac

CureVac is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing and optimizing this versatile biological molecule for medical purposes. The principle of CureVac`s proprietary technology is the use of optimized mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases. In July 2020, CureVac entered in a collaboration with GSK to jointly develop new products in prophylactic vaccines for infectious diseases based on CureVac`s second-generation mRNA technology. This collaboration was later extended to the development of second-generation COVID-19 vaccine candidates, and modified mRNA vaccine technologies. Based on its proprietary technology, CureVac has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. CureVac had its initial public offering on the New York Nasdaq in August 2020. It is headquartered in Tübingen, Germany, and employs more than 700 people at its sites in Tübingen, Frankfurt, and Boston, USA.

Akers Biosciences

Akers Biosciences is a Thorofare, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.